CCST9006 Chap.4 Transplantation Science and Choices
Transplantation Science and Choices
Compatibility and scarcity are different problems
Transplantation can restore lost function, but donated material may be recognised as non-self and transplantable organs remain scarce. ABO antigens and antibodies illustrate immediate incompatibility, while HLA and minor antigens extend the matching problem.
Host cells, antibodies, complement and natural killer cells can contribute to graft injury through different routes.
Time helps locate the mechanism
Hyperacute rejection appears within minutes or hours and points to pre-existing antibodies and vascular thrombosis. Acute rejection can be cellular or humoral over days and weeks.
Chronic rejection develops over months or years through repeated injury, vessel narrowing and fibrosis. Matching, immunosuppression and future tolerance strategies address different parts of this sequence, while paired exchange, organoids and xenotransplantation address different parts of scarcity.
What this chapter covers
- 01
ABO antigens and antibodies
- 02
HLA and minor histocompatibility antigens
- 03
Cell-mediated and humoral injury
- 04
Hyperacute, acute and chronic rejection
- 05
Matching and immunosuppression
- 06
Paired exchange, organoids and xenotransplantation
Worked example · free
Choose what paired exchange solves
- 3Name the compatibility problem.
- 2Explain the exchange mechanism.
- 3State the scarcity and coordination limits.
Key terms
- Allograft
- A graft between genetically different members of the same species.
- Crossmatch
- A test for recipient antibodies that react against proposed donor targets.
- Hyperacute Rejection
- Immediate graft injury driven by pre-existing antibodies and vascular thrombosis.
- Chronic Rejection
- Progressive graft loss involving vascular narrowing, inflammation and fibrosis.
- Paired Exchange
- Exchange between incompatible donor-recipient pairs to create compatible pathways.
Transplantation Science and Choices FAQ
Why can a graft fail within hours?
Very rapid failure suggests pre-existing recipient antibodies against donor ABO, HLA or other vascular targets. Binding can activate complement, injure endothelium and promote thrombosis. The timing points away from a newly developed response and toward compatibility testing and crossmatch as the first evidence to review.
How are acute and chronic rejection different?
Acute rejection develops over days or weeks and can involve cellular infiltration or newly generated donor-specific antibodies. Chronic rejection unfolds over months or years with repeated immune and non-immune injury, vessel narrowing and fibrosis. It is generally harder to reverse and requires long-term monitoring.
Does better matching solve organ scarcity?
Better matching reduces incompatibility and may improve graft outcomes, but it does not create enough organs for everyone waiting. Paired exchange can unlock donation among willing incompatible pairs, while other approaches seek new tissue sources. Allocation still requires a priority rule even when matching improves.
Why does timing help identify rejection?
The immune resources required for different mechanisms appear on different timescales. Failure within hours points toward antibodies already present before transplantation, while cellular or newly generated antibody responses take longer. Progressive months-to-years decline suggests repeated injury, vessel narrowing and fibrosis rather than one immediate mismatch.
What is the promise of donor-specific tolerance?
Tolerance aims to teach the recipient immune system to accept donor tissue rather than suppress immune activity globally. The promise is graft protection with less broad immunosuppression. Evaluation must ask whether the effect is specific, durable and safe, because partial tolerance could leave both rejection and infection risks.
How do paired and pooled exchanges differ?
Paired exchange links two incompatible donor-recipient pairs, while a pool can connect three or more. Larger chains may unlock more matches but add coordination and withdrawal dependencies. Both approaches rearrange willing donation; neither creates a pathway for everyone without a willing donor.
Why is compatibility not a guarantee of graft survival?
Matching reduces selected immune risks, but later cellular responses, antibodies, infection, drug toxicity and non-immune injury can still damage function. Treat compatibility as one prevention layer. Continued monitoring and appropriate immune control remain necessary after an initially successful transplant.
Assessment move
Build a four-column rejection table from memory: time, immune driver, tissue damage and response. Then take each scarcity strategy and state which constraint it changes. Finish by naming the remaining problem. This prevents compatibility, immune control and fair allocation from collapsing into one answer. Next, explain host-versus-graft and graft-versus-host without notes, naming the attacking side first.
Work one paired-exchange scenario and one future-source scenario, comparing eligibility, evidence maturity, time to benefit and burden. End every response with the stakeholder who owns the remainder: clinicians monitor immune risk, allocation bodies manage priority, and research teams investigate evidence gaps.
Working through Transplantation Science and Choices in CCST9006? Sia is AskSia’s AI Health and Medicine tutor — ask any CCST9006 Transplantation Science and Choices question and get a clear, step-by-step explanation grounded in how CCST9006 is taught and assessed. Read this chapter free, then take your hardest questions to Sia.